#USA #Toronto #Xtalks #GTN leakage #RIS Rx

Understanding the $90B Leakage Challenge in Pharmaceuticals

The pharmaceutical industry is grappling with a staggering issue - an estimated $90 billion in annual revenue leakage primarily attributed to Gross-to-Net (GTN) mismanagement. This problem is more than just numbers; it has significant implications for patient care and industry sustainability. To delve deeper into this complex issue, Xtalks is hosting a free webinar designed to illuminate the intricacies of GTN revenue leakage and explore robust solutions.

What Is GTN Leakage?

Gross-to-Net leakage refers to the gap between a pharmaceutical company's expected revenue and the actual revenue achieved after various deductions. These deductions can stem from several factors, including copay accumulators, maximizers, and pharmacy copay misuse. This leakage not only impacts the bottom line but also disrupts patient access to critical medications.

During the upcoming webinar, attendees will gain valuable insights into the causes of this leakage and the severe consequences it has on patients and healthcare systems. The information shared will help attendees understand the structural contributors to GTN issues and why traditional approaches, such as retrospective audits, often fall short in providing solutions.

Why Attend the Webinar?

This webinar promises to deliver practical knowledge on how to mitigate GTN leakage effectively. Key topics include:

• - Identifying Structural Drivers: Participants will learn about specific elements causing GTN revenue loss, such as alternative funding programs and pharmacy-level dynamics that contribute to financial misalignment.
• - Impact on Patient Experience: Understanding how GTN revenue leakage can affect patient access and continuity of care is crucial. Attendees will explore how these financial losses can compromise the overall patient experience, making it imperative to tackle these issues head-on.
• - Strategies for Real-Time Intervention: The discussion will highlight the importance of implementing real-time intervention tactics during program enrollment. This proactive approach is essential for identifying and addressing misalignments in benefit designs early on, thereby reducing avoidable revenue leakage.

Speakers and Insights

The webinar will feature industry experts, including Gerard Rivera, CEO and Co-Founder of RIS Rx, and Stephen Hom, COO and Co-Founder, who bring extensive knowledge from frontline pharmacy and patient access workflows. Their experience positions them to provide attendees with nuanced insights into how systemic failures can be rectified.

The Importance of Proactive Strategies

With growing pressure on profitability in the pharmaceutical sector, it is crucial that companies move beyond reactive measures. As GTN performance becomes a focal point for board members, adopting a forward-thinking approach can significantly enhance revenue predictability and accessibility outcomes for patients. Participants will leave the webinar equipped with actionable strategies tailored to their organizations.

How to Join

The live webinar is scheduled for Monday, March 30, 2026, at 11 am EDT (5 pm CEST), and interested participants are encouraged to register early. Furthermore, there will be opportunities for questions and further discussion, allowing attendees to engage directly with the speakers.

For more information and to secure a spot, visit the Xtalks website: The $90B Leakage Problem Webinar.

About Xtalks

Xtalks is a trusted online platform catering to professionals in the life sciences, providing timely information, collaborative insights, and educational tools that propel the industry forward. Their webinars are renowned for combining expert advice with the latest industry developments – making them a pivotal resource for healthcare professionals.

About RIS Rx

RIS Rx is a healthcare technology firm dedicated to helping pharmaceutical manufacturers safeguard their revenue through cutting-edge solutions. By leveraging real-time analytics and skilled pharmacists, RIS Rx is committed to optimizing operations and ensuring patients receive the financial assistance they deserve. In 2025, they protected over $1 billion in revenue for their clients, showcasing the effectiveness of their proactive measures.

Engage in this informative session and be part of the solution to one of the most pressing issues in the pharmaceutical landscape today.